
FDA Lifts Black Box Warning from Combination Long-Acting Bronchodilator/Corticosteroid Inhalers
In 2011, the Food & Drug Administration ordered post-market safety trials to be conducted on combination long-acting beta agonist (LABA) and inhaled corticosteroid (ICS) inhalers. This review was prompted by the discovery that using LABA inhalers alone resulted in an increased risk of asthma-related death. LABAs are medications that relax the muscles of the airways so they … Read more